More Data Needed for Neoadjuvant Tx for Bile Duct Cancer

In a debate held recently on the use of neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma, both sides agreed that more research is needed.

Related Keywords

Massachusetts ,United States ,Houston ,Texas ,Boston ,California ,American ,Cristinar Ferrone ,Los Angeles ,S Tran Cao ,Motaz Qadan ,Tran Cao ,International Conference Of Surgical Cancer Care ,University Of Texas Md Anderson Cancer Center ,American Cancer Society ,American Society For Clinical Oncology ,International Conference ,Surgical Cancer Care ,Cancer Center ,American Cancer ,American Society ,Gapontsev Family Endowed Chair ,Massachusetts General Hospital ,Medscape Medical ,Drugs Become Obsolete ,Noncolorectal Gastrointestinal Cancer ,Oncolorectal Gi Cancer ,Neoadjuvant ,Hepatocellular Carcinoma ,Liver Cancer ,Dcc ,Hepatocellular Cancer ,Ancer Liver ,Ancer Hepatocellular ,Cancer ,Alignant Neoplasia ,Arcinoma ,Toxicology ,Surgery ,Oncological Surgery ,Pancreatic Surgery ,Biliary Tract ,Cholangiocarcinoma ,Obile ,Chemotherapy ,Tumor ,Patient Safety ,Clinical Research ,Clinical Trials ,Linical Stu ,